Aravive (ARAV) reported Friday positive new data from its phase 1b trial evaluating its AVB-500 batiraxcept candidate in combination with cabozantinib in...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | River Oaks Tower Houston, Texas 77098 |
| Phone | +1.936.355.1910 |
| Number of Employees | 14 |
| President, Chief Executive Officer & Director | Gail Frances McIntyre |
| Chief Financial Officer | Vinay Shah |
| Chief Medical Officer | Reshma Rangwala |
| Vice President-Clinical Operations | Amy Franke |
| Price Open | $3.13 |
| Previous Close | $3.09 |
| 52 Week Range | $2.41 - 9.95 |
| Market Capitalization | $53.1 M |
| Shares Outstanding | 21.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/15/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.58 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.4 M |
| Net Profit Margin | -249.06% |
| Return on Equity | -51.44% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
